B cell depleting therapies, such as anti-CD38 and anti-BCMA treatment commonly used in treating MM, have shown a detrimental effect on antibody levels and may result in impaired B cell differentiation, decreased plasmablasts and plasma cells and compromised T cell response (60–62). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.